Literature DB >> 9712178

PACAP and PACAP receptors in insulin producing tissues: localization and effects.

K Filipsson1, F Sundler, J Hannibal, B Ahrén.   

Abstract

We have studied the localization, receptor occupancy and potency of the neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) in insulin-producing tissues. Immunocytochemistry showed that PACAP-like immunoreactivity (PACAP-IR) was localized to pancreatic nerves with accumulation in intrapancreatic ganglia in both mouse and rat. In contrast, PACAP-IR could not be demonstrated in endocrine cells. Furthermore, in situ hybridization, using oligodeoxyribonucleotide probes recognizing mRNA for PACAP receptors, demonstrated that mouse and rat pancreas, and the insulinoma cell lines HIT-T15 and RINm5F, expressed both the PACAP type 1 and the VIP2/PACAP receptors. Moreover, both PACAP27 and PACAP38 dose-dependently (0.1 nM to 100 nM) and equipotently stimulated insulin secretion in isolated mouse and rat islets and in HIT-T15 and RINm5F cells. Furthermore, in mouse islets, vasoactive intestinal polypeptide (VIP) was of equal potency as PACAP at stimulating insulin secretion. In mouse, PACAP also stimulated insulin secretion in a subfraction of the isolated islets also at the low dose of 1 fM. Thus, (1) PACAP is exclusively a neuropeptide in the pancreas, (2) insulin-producing cells express PACAP type 1 and VIP2/PACAP receptors and (3) the two forms of PACAP equipotently stimulate insulin secretion. Based on these results, we suggest that PACAP is involved in the neural regulation of insulin secretion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712178     DOI: 10.1016/s0167-0115(98)00037-8

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

Review 1.  Signalling in response to sub-picomolar concentrations of active compounds: Pushing the boundaries of GPCR sensitivity.

Authors:  Srgjan Civciristov; Michelle L Halls
Journal:  Br J Pharmacol       Date:  2019-04-05       Impact factor: 8.739

2.  PAC1 receptor-deficient mice display impaired insulinotropic response to glucose and reduced glucose tolerance.

Authors:  F Jamen; K Persson; G Bertrand; N Rodriguez-Henche; R Puech; J Bockaert; B Ahrén; P Brabet
Journal:  J Clin Invest       Date:  2000-05       Impact factor: 14.808

Review 3.  Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications.

Authors:  Satomi Onoue; Shingen Misaka; Shizuo Yamada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-01-03       Impact factor: 3.000

4.  Neuronal signals regulate obesity induced β-cell proliferation by FoxM1 dependent mechanism.

Authors:  Junpei Yamamoto; Junta Imai; Tomohito Izumi; Hironori Takahashi; Yohei Kawana; Kei Takahashi; Shinjiro Kodama; Keizo Kaneko; Junhong Gao; Kenji Uno; Shojiro Sawada; Tomoichiro Asano; Vladimir V Kalinichenko; Etsuo A Susaki; Makoto Kanzaki; Hiroki R Ueda; Yasushi Ishigaki; Tetsuya Yamada; Hideki Katagiri
Journal:  Nat Commun       Date:  2017-12-05       Impact factor: 14.919

5.  Epigenetic Profiles Reveal That ADCYAP1 Serves as Key Molecule in Gestational Diabetes Mellitus.

Authors:  Xue Li; Wenhong Yang; Yanning Fang
Journal:  Comput Math Methods Med       Date:  2019-08-14       Impact factor: 2.238

Review 6.  Neuroprotective Potential of Pituitary Adenylate Cyclase Activating Polypeptide in Retinal Degenerations of Metabolic Origin.

Authors:  Robert Gábriel; Etelka Pöstyéni; Viktória Dénes
Journal:  Front Neurosci       Date:  2019-10-09       Impact factor: 4.677

Review 7.  Role of pituitary adenylate cyclase-activating polypeptide in modulating hypothalamic-pituitary system.

Authors:  Aki Oride; Haruhiko Kanasaki; Satoru Kyo
Journal:  Reprod Med Biol       Date:  2018-03-31

8.  PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin.

Authors:  John P Vu; Deepinder Goyal; Leon Luong; Suwan Oh; Ravneet Sandhu; Joshua Norris; William Parsons; Joseph R Pisegna; Patrizia M Germano
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-09-03       Impact factor: 4.052

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.